Xenon Pharmaceuticals (XENE) Expected to Announce Quarterly Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to be releasing its earnings data after the market closes on Thursday, February 27th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.89) per share and revenue of $0.31 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $37.65 on Wednesday. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -13.35 and a beta of 1.20. The business has a 50-day moving average of $39.39 and a 200-day moving average of $40.35. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,267,731. This trade represents a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders sold 57,492 shares of company stock worth $2,334,969 over the last three months. Insiders own 5.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on XENE. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $57.38.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.